Radius Health, Inc. (RDUS), a company focused on developing endocrine therapeutics in the areas of osteoporosis and oncology, presented results from "Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density or BMD in Patients Treated with Abaloparatide Followed by Alendronate - Results from Phase 3 ACTIVExtend" at ENDO 2018, the Endocrine Society's 100th Annual Meeting and Expo in Chicago.
from RTT - Biotech http://ift.tt/2FRiMn0
via IFTTT
No comments:
Post a Comment